A number of other analysts have also commented on BLFS. ValuEngine lowered BioLife Solutions from a “hold” rating to a “sell” rating in a research note on Thursday. Zacks Investment Research lowered BioLife Solutions from a “buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Maxim Group set a $26.00 price target on BioLife Solutions and gave the company a “buy” rating in a research note on Tuesday, September 17th. HC Wainwright assumed coverage on BioLife Solutions in a research note on Monday, July 22nd. They set a “buy” rating and a $23.00 price target on the stock. Finally, Northland Securities lifted their price target on BioLife Solutions from $18.00 to $22.00 and gave the company an “outperform” rating in a research note on Wednesday, September 4th. One analyst has rated the stock with a sell rating and six have given a buy rating to the stock. BioLife Solutions has an average rating of “Buy” and a consensus target price of $18.40.
BioLife Solutions stock traded down $0.48 during midday trading on Thursday, reaching $14.77. The company’s stock had a trading volume of 180,000 shares, compared to its average volume of 175,961. BioLife Solutions has a 52 week low of $9.15 and a 52 week high of $22.44. The company has a current ratio of 6.49, a quick ratio of 7.71 and a debt-to-equity ratio of 0.01. The business has a 50-day moving average price of $16.36 and a 200-day moving average price of $17.71. The stock has a market cap of $301.67 million, a PE ratio of 105.50 and a beta of 1.35.
Institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. acquired a new position in shares of BioLife Solutions in the second quarter worth approximately $30,000. Alpine Woods Capital Investors LLC acquired a new position in shares of BioLife Solutions in the second quarter worth approximately $170,000. Morgan Stanley lifted its stake in shares of BioLife Solutions by 17.5% in the second quarter. Morgan Stanley now owns 11,506 shares of the medical equipment provider’s stock worth $195,000 after acquiring an additional 1,713 shares during the period. Menta Capital LLC acquired a new position in shares of BioLife Solutions in the second quarter worth approximately $202,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in shares of BioLife Solutions in the second quarter worth approximately $283,000. 46.22% of the stock is currently owned by institutional investors.
BioLife Solutions Company Profile
BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.
Featured Article: Candlestick
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.